close
Add to watchlist
PDL BioPharma Inc (PDLI) Healthcare, Biotechnology & Drugs
PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The company licenses its technologies to make and sell antibodies that bind to respiratory syncytial virus, as well as antibodies that bind to the alpha subunit of the VLA-4 integrin. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 6.23 |
| Volume | (mio) 1.42 |
| Volume Avg | (mio) 2.07 |
| 52 Week High | 6.70 |
| 52 Week Low | 5.15 |
| PE | 5.45 |
| PE (group average) | 39 |
| EPS Year | 1.16 |
| EPS change Q/Q | -1000% |
| EPS change Q/Q Yr ago | 45.45% |
| EPS change Q/Q next Q est | -25.58% |
| EPS change Y/Y | 70.45% |
| REV change Q/Q | 9.46% |
| REV change Q/Q Yr ago | 34.14% |
| EPS next Q est | 0.43 |
| EPS next Y est | 1.65 |
| Divident Annual | 0.60 |
| Dividend Yield | 9.63% |